10/510,680 YONG CHU 4-25-2006

$%^STN;HighlightOn=;**HighlightOff=**;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptaylc1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:13:58 ON 25 APR 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:14:03 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0
DICTIONARY FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10510680\10510680c.str



chain nodes :
6 7 8 10 11 12 13
ring nodes :

1 2 3 4 5
ring/chain nodes :
9
chain bonds :
1-10 3-6 6-7 7-8 7-9 10-11 11-12 12-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 3-6 4-5 6-7 7-8 10-11 11-12 12-13
exact bonds :
1-10 7-9

G1:O,S,SO2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 O,S,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:14:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 982 TO ITERATE

100.0% PROCESSED 982 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 17760 TO 21520
PROJECTED ANSWERS: 10 TO 388

L2 10 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:14:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18643 TO ITERATE

100.0% PROCESSED 18643 ITERATIONS 149 ANSWERS
SEARCH TIME: 00.00.01

L3 149 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 166.94 | 167.15

FILE 'CAPLUS' ENTERED AT 11:14:46 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 24 Apr 2006 (20060424/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 58 L3

=>
Uploading C:\Program Files\Stnexp\Queries\10510680\10510680d.str



chain nodes :
6 7 8 10 11 12 13
ring nodes :
1 2 3 4 5
ring/chain nodes :
9
chain bonds :
1-10 3-6 6-7 7-8 7-9 10-11 11-12 12-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 3-6 4-5 6-7 7-8 10-11 11-12 12-13
exact bonds :
1-10 7-9

G1:O,S,SO2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



G1 O,S,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l5
REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 11:17:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 982 TO ITERATE

100.0% PROCESSED 982 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 17760 TO 21520
PROJECTED ANSWERS: 4 TO 200

L6 4 SEA SSS SAM L5

L7 1 L6

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.46 169.89

FILE 'REGISTRY' ENTERED AT 11:17:15 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0
DICTIONARY FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10510680\10510680d.str



chain nodes :
6 7 8 10 11 12 13
ring nodes :
1 2 3 4 5
ring/chain nodes :
9
chain bonds :
1-10 3-6 6-7 7-8 7-9 10-11 11-12 12-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 3-6 4-5 6-7 7-8 10-11 11-12 12-13
exact bonds :
1-10 7-9

G1:O,S,SO2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom

L8 STRUCTURE UPLOADED

=> d
L8 HAS NO ANSWERS
L8 STR



G1 O,S,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l8
SAMPLE SEARCH INITIATED 11:17:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 982 TO ITERATE

100.0% PROCESSED 982 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 17760 TO 21520
PROJECTED ANSWERS: 4 TO 200

L9 4 SEA SSS SAM L8

=> s l8 full
FULL SEARCH INITIATED 11:17:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18643 TO ITERATE

100.0% PROCESSED 18643 ITERATIONS 68 ANSWERS
SEARCH TIME: 00.00.01

L10 68 SEA SSS FUL L8

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 166.94 336.83

FILE 'CAPLUS' ENTERED AT 11:17:54 ON 25 APR 2006

FILE COVERS 1907 - 25 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 24 Apr 2006 (20060424/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	337.29

FILE 'CAPLUS' ENTERED AT 11:18:03 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 24 Apr 2006 (20060424/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l10
L11 4 L10

=> d ibib abs hitstr tot

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:546475 CAPLUS
DOCUMENT NUMBER: 141:106362
TITLE: Preparation of 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
INVENTOR(S): Mehta, Anita; Gupta, Jang Bahadur; Sarma, Pakala Kumara Savithru
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056767	A1	20040708	WO 2002-IB5590	20021223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002347552	A1	20040714	AU 2002-347552	20021223
EP 1583741	A1	20051012	EP 2002-783480	20021223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: WO 2002-IB5590 A 20021223

102(e)

OTHER SOURCE(S): CASREACT 141:106362; MARPAT 141:106362
GI



AB Title muscarinic receptor antagonists I (X = O, NH, etc.; R1 = OH, etc.; R2 = H, halo, alkyl; R3 = H, OH, etc.; R4, R5, R6 = H, alkyl; ; Z = CH2, SO2, carbonyl; W = alkylene, etc.; R = alkyl, aryl, etc.), useful for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors, are prepared
The affinity of these compds. for M2 and M3 muscarinic receptor subtype was tested. For example, (3S)-1-benzylpyrrolidin-3-yl cyclopentyl(hydroxy)phenylacetate was prepared and had pKi = 6.13/7.17 for

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
the M2 and M3 receptor subtype resp.
IT 719278-65-6P 719278-66-7P 719278-72-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-substituted-3-pyrrolidine derivs. as muscarinic receptor antagonists)
RN 719278-65-6 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, (3S)-1-[[4-(trifluoromethyl)phenyl]sulfonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719278-66-7 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, (3S)-1-[(4-nitrophenyl)sulfonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 719278-72-5 CAPLUS
CN Benzeneacetic acid, α-cyclopentyl-α-hydroxy-, (3S)-1-[(4-bromophenyl)sulfonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Current application

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:837081 CAPLUS
DOCUMENT NUMBER: 139:337885
TITLE: Preparation of acyloxypyrrolidinium salts as M3 muscarinic antagonists
INVENTOR(S): Prat Quinones, Maria; Fernandez Forner, Maria Dolors
PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087094	A2	20031023	WO 2003-EP3786	20030411
WO 2003087094	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2206021	A1	20040501	ES 2002-889	20020416
ES 2206021	B1	20050801		
CA 2482536	AA	20031023	CA 2003-2482536	20030411
AU 2003233967	A1	20031027	AU 2003-233967	20030411
EP 1497284	A2	20050119	EP 2003-727294	20030411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009167	A	20050125	BR 2003-9167	20030411
CN 1662527	A	20050831	CN 2003-813892	20030411
NO 2004004826	A	20050114	NO 2004-4826	20041105
US 2005282875	A1	20051222	US 2005-510660	20050720

PRIORITY APPLN. INFO.: ES 2002-889 A 20020416
WO 2003-EP3786 W 20030411

OTHER SOURCE(S): MARPAT 139:337885
GI



X⁻ I





II

AB Pyrrolidinium derivs. I [R = (un)substituted Ph, naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl, benzo[1,3]dioxolyl, biphenyl, heteroarom.; R1 = alkyl; R2 = CR3R4R5, Q; R3 = 2-furyl, 3-furyl, 2-thienyl, 3-thienyl; R4 = 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, cycloalkyl; R5 = H, OH, Me, CH2OH; Q1 = CH2, CH2CH2, O, OCH2, S, SCH2, CH:CH; A = (un)substituted CH:CH, CH2, CO, O, S, S(O), SO2, NH; m = 0-8; n = 0-4] were prepared for use in therapy as antagonists of M3 muscarinic receptors (no data). Thus, (3R)-3-pyrrolidinol was treated with 2-(3-bromopropyl)thiophene to give (3R)-1-(3-thien-2-ylpropyl)pyrrolidinol which was treated with Me 2-hydroxy-2,2-dithen-2-ylacetate and quaternized to give the pyrrolidinium salt II.

IT **616865-64-6P 616865-65-7P**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acyloxypyrrolidinium salts as M3 muscarinic antagonists)

RN 616865-64-6 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(3-phenoxypropyl)-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-65-7 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(3-phenoxypropyl)-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

IT **616866-05-8P 616866-06-9P 616866-07-0P**
616866-08-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acyloxypyrrolidinium salts as M3 muscarinic antagonists)

RN 616866-05-8 CAPLUS
CN 2-Thiopheneacetic acid, α-hydroxy-α-2-thienyl-, (3R)-1-(2-phenoxyethyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616866-06-9 CAPLUS
CN 2-Thiopheneacetic acid, α-hydroxy-α-2-thienyl-, (3R)-1-(2-phenoxyethyl)-3-pyrrolidinyl ester, ethanedioate (1:1) (salt)

(9CI) (CA INDEX NAME)

CM 1

CRN 616866-05-8
CMF C22 H23 N O4 S2

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 616866-07-0 CAPLUS
CN 2-Thiopheneacetic acid, α-hydroxy-α-2-thienyl-, (3R)-1-(3-phenoxypropyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 616866-08-1 CAPLUS
CN 2-Thiopheneacetic acid, α-hydroxy-α-2-thienyl-, (3R)-1-(3-phenoxypropyl)-3-pyrrolidinyl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 616866-07-0
CMF C23 H25 N O4 S2

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4

IT **616865-58-8P 616865-59-9P 616865-60-2P**
616865-62-4P 616865-63-5P 616865-76-0P
616865-77-1P 616865-78-2P 616865-79-3P
616865-80-6P 616865-81-7P 616865-82-8P
616865-86-2P 616865-87-3P 616865-88-4P
616865-89-5P 616865-90-8P 616865-91-9P
616865-92-0P 616865-93-1P 616865-94-2P
616865-95-3P 616865-96-4P 616866-00-3P
616866-02-5P 616866-04-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acyloxypyrrolidinium salts as M3 muscarinic antagonists)

RN 616865-58-8 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(2-phenoxyethyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-59-9 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(2-phenoxyethyl)-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-60-2 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(2-phenoxyethyl)-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-62-4 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(3-phenoxypropyl)-, bromide (9CI) (CA INDEX NAME)



● Br⁻

RN 616865-63-5 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-methyl-1-(3-phenoxypropyl)-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Absolute stereochemistry.



● Br⁻

RN 616865-79-3 CAPLUS
CN Pyrrolidinium, 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-1-methyl-3-[(9H-xanthen-9-ylcarbonyl)oxy]-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-80-6 CAPLUS
CN Pyrrolidinium, 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-1-methyl-3-[(9H-xanthen-9-ylcarbonyl)oxy]-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-76-0 CAPLUS
CN Pyrrolidinium, 3-[(cyclohexyl-2-furanylhydroxyacetyl)oxy]-1-methyl-1-[2-(phenylmethoxy)ethyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-77-1 CAPLUS
CN Pyrrolidinium,
3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[2-(phenylmethoxy)ethyl]-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-78-2 CAPLUS
CN Pyrrolidinium,
3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[2-(phenylmethoxy)ethyl]-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)



● Br⁻

RN 616865-81-7 CAPLUS
CN Pyrrolidinium, 1-methyl-1-[3-(2-methylphenoxy)propyl]-3-[(9H-xanthen-9-ylcarbonyl)oxy]-, bromide, (1S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-82-8 CAPLUS
CN Pyrrolidinium, 1-methyl-1-[3-(2-methylphenoxy)propyl]-3-[(9H-xanthen-9-ylcarbonyl)oxy]-, bromide, (1R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-86-2 CAPLUS
CN Pyrrolidinium, 1-[3-(2-benzothiazolyloxy)propyl]-3-[[(2R)-cyclohexyl-2-furanylhydroxyacetyl]oxy]-1-methyl-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Cl⁻

RN 616865-87-3 CAPLUS
CN Pyrrolidinium, 1-[3-(2-benzothiazolyloxy)propyl]-3-[[(2S)-cyclohexyl-2-furanylhydroxyacetyl]oxy]-1-methyl-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-90-8 CAPLUS
CN Pyrrolidinium, 3-[[(2S)-cyclohexyl-2-furanylhydroxyacetyl]oxy]-1-ethyl-1-[3-(phenylthio)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-91-9 CAPLUS
CN Pyrrolidinium,
3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[3-(phenylthio)propyl]-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-92-0 CAPLUS
CN Pyrrolidinium,
3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[3-



● Cl⁻

RN 616865-88-4 CAPLUS
CN Pyrrolidinium, 1-[3-(2-benzothiazolyloxy)propyl]-3-[(cyclohexyl-2-furanylhydroxyacetyl)oxy]-1-methyl-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Cl⁻

RN 616865-89-5 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclohexyl-2-furanylhydroxyacetyl]oxy]-1-ethyl-1-[3-(phenylthio)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

(phenylthio)propyl]-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-93-1 CAPLUS
CN Pyrrolidinium,
3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-, bromide, (1S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-94-2 CAPLUS
CN Pyrrolidinium,
3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-methyl-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-, bromide, (1R,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616865-95-3 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-[3-(4-

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methoxyphenoxy)propyl]-1-methyl-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻.

RN 616865-96-4 CAPLUS
CN Pyrrolidinium, 3-[[(2R)-cyclopentylhydroxyphenylacetyl]oxy]-1-[3-(4-methoxyphenoxy)propyl]-1-methyl-, bromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br⁻

RN 616866-00-3 CAPLUS
CN Pyrrolidinium, 3-[(hydroxydi-2-thienylacetyl)oxy]-1-[3-(3-hydroxyphenoxy)propyl]-1-methyl-, (3S)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 616865-99-7
CMF C24 H28 N O5 S2

Absolute stereochemistry.



L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 71-47-6
CMF C H O2

O═CH—O⁻

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 2

CRN 71-47-6
CMF C H O2

O═CH—O⁻

RN 616866-02-5 CAPLUS
CN Pyrrolidinium, 1-[3-(3-cyanophenoxy)propyl]-3-[(cyclohexyl-2-furanylhydroxyacetyl)oxy]-1-methyl-, (3R)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 616866-01-4
CMF C27 H35 N2 O5

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2

O═CH—O⁻

RN 616866-04-7 CAPLUS
CN Pyrrolidinium, 3-[(cyclohexyl-2-furanylhydroxyacetyl)oxy]-1-methyl-1-[3-(1-naphthalenyloxy)propyl]-, (3R)-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 616866-03-6
CMF C30 H38 N O5

Absolute stereochemistry.

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:78387 CAPLUS
DOCUMENT NUMBER: 134:131538
TITLE: Preparation of imidazoimidazoles and triazoles as anti-inflammatory agents
INVENTOR(S): Wu, Jiang-Ping; Kelly, Terence Alfred; Lemieux, Rene M.; Goldberg, Daniel R.; Emeigh, Jonathan Emilian; Sorcek, Ronald J.
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 368 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007440	A1	20010201	WO 2000-US18884	20000712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6492408	B1	20021210	US 2000-604312	20000627
CA 2383017	AA	20010201	CA 2000-2383017	20000712
BR 2000012666	A	20020409	BR 2000-12666	20000712
EP 1216247	A1	20020626	EP 2000-948618	20000712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200160	T2	20021021	TR 2002-200200160	20000712
JP 2003505460	T2	20030212	JP 2001-512524	20000712
EE 200200028	A	20030415	EE 2002-28	20000712
NZ 517217	A	20040227	NZ 2000-517217	20000712
AU 776496	B2	20040909	AU 2000-62091	20000712
BG 106312	A	20020930	BG 2002-106312	20020116
ZA 2002000428	A	20030117	ZA 2002-428	20020117
NO 2002000275	A	20020204	NO 2002-275	20020118
US 2003203955	A1	20031030	US 2002-195973	20020716
US 6689804	B2	20040210		
HK 1048637	A1	20050225	HK 2003-100839	20030206
US 2004116426	A1	20040617	US 2003-672412	20030925

PRIORITY APPLN. INFO.:

US 1999-144905P	P	19990721
US 1999-150939P	P	19990826
US 2000-604312	A1	20000627
WO 2000-US18884	W	20000712
US 2002-195973	A3	20020716

OTHER SOURCE(S): MARPAT 134:131538
GI

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

AB Compds. I [A1 = N, CH; A2 = N, CH, CR'; R' = halo, cyano, alkoxy, alkoxycarbonyl, alkylsulfonyl; D = N, CH, CR1, C(SO2R1), C[S(:O)R1], C(CHO), C(SR1a), C(OR1a), C(NHR1a); R1, R1a = (substituted) alkyl, cycloalkyl, aryl, or heteroaryl groups, alkyl groups containing 2-6 carbons substituted with carboxylate, phosphonate, sulfonate, amidine, or guanidine moieties, amino, halogen, cyano; R3 = H, alkyl, cycloalkyl, alkoxy or amino substituted alkyl, cycloalkyl; R4 = substituted arylmethyl; R5 = Cl, F3C; R7 = H, halo, Me, cyano, O2N, F3C; X = O, S; if Z = N or CH, R7 = Cl, F3C, cyano, O2N; Z = N, CR6 where R6 = H, halo, Me, cyano, F3C), based mostly on imidazo[1,2-a]imidazole and imidazo[1,2-a]triazole nuclei, are prepared as inhibitors of the binding of leukointegrins to cell adhesion mols. in the treatment or prevention of inflammatory and immune cell-mediated diseases. E.g., (R)-I (A1 = N; A2 = D = CH; R3 = Me; R4 = 4-BrC6H4CH2; R5 = R7 = Cl; X = O; Z = CH) (II) was prepared from (R)-α-methyl-4-bromophenylalanine Me ester and 3,5-dichlorophenylisothiocyanate by heating in 1,4-dioxane to give a thiohydrantoin which was treated with N-(triphenylphosphoranylidene)-1,3-dioxolan-2-ylmethylamine [prepared from 2-(azidomethyl)-1,3-dioxolane and triphenylphosphine] to give a dioxolanylmethyliminoimidazolidinone derivative; treatment of the intermediate with trifluoroacetic acid and heating at 90° overnight gave II with m.p. 36-37.5°. I inhibited binding of leukointegrins to cell adhesion mols. with Kd<10 μM.

IT **321720-00-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazoimidazole and imidazotriazole derivs. as inhibitors of leukointegrin binding to cell adhesion mols. in the treatment of inflammatory and immune-cell mediated diseases)

RN 321720-00-7 CAPLUS
CN 3-Pyrrolidinol, 1-[[(3R)-3-[(4-bromophenyl)methyl]-1-(3,5-dichlorophenyl)-2,3-dihydro-3-methyl-2-oxo-1H-imidazo[1,2-a]imidazol-5-yl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:326202 CAPLUS
DOCUMENT NUMBER: 126:293362
TITLE: Heterocyclic phenylpropenoates and analogs as fungicidal compounds.
INVENTOR(S): Aspinall, Ian Henry
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: Brit. UK Pat. Appl., 25 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2303131	A1	19970212	GB 1995-14069	19950710
PRIORITY APPLN. INFO.:			GB 1995-14069	19950710

OTHER SOURCE(S): MARPAT 126:293362
GI



I



II

AB Title compds. I or stereoisomers thereof [wherein R1 = H, halo, alkyl, alkoxy; A = CR2:CR3 (R2 and R3 = H, or form (un)substituted fused benzene ring), or A = CH(R4)X (R4 = H or OH or derivative, and X = CH2, O, S or NR5; R5 = H or alkyl); n = 1-3; W = C(:CHOMe)CO2CH3, C(:CHOMe)CONR6R7, C(:NOMe)CO2CH3, or C(:NOMe)CONR6R7; R6, R7 = H or alkyl] have fungicidal activity, and may be used for treating plants. For example, (E)-Me 2-[2-(phthalimidooxymethyl)phenyl]-3-methoxypropenoate underwent hydrazinolysis of the phthalimide protecting group (92%), and the resulting oxyamino compound was cyclized with Br(CH2)5Br in the presence of Et3N (29%) to give title compound II. As a 100-ppm foliar spray, II reduced the degree of infection of host plants, by 5 of 6 tested phytopathogens, including Erysiphe graminis tritici and Puccinia recondita, to 0% of control.

IT **189177-56-8P 189177-59-1P 189177-61-5P 189177-62-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic of [(heterocycloxymethyl)phenyl]propenoates and analogs as fungicides)

RN 189177-56-8 CAPLUS
CN Benzeneacetic acid, 2-[[[3-(benzoyloxy)-1-pyrrolidinyl]oxy]methyl]-α-(methoxymethylene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.



RN 189177-59-1 CAPLUS
CN Benzeneacetic acid, 2-[[[3-[(3-chlorobenzoyl)oxy]-1-pyrrolidinyl]oxy]methyl]-α-(methoxymethylene)-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 189177-61-5 CAPLUS
CN Benzeneacetic acid, α-(methoxymethylene)-2-[[[3-[[3-(trifluoromethyl)benzoyl]oxy]-1-pyrrolidinyl]oxy]methyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 199177-62-6 CAPLUS
CN Benzeneacetic acid, α-(methoxymethylene)-2-[[[3-[(2-methylbenzoyl)oxy]-1-pyrrolidinyl]oxy]methyl]-, methyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.82	359.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

STN INTERNATIONAL LOGOFF AT 11:19:34 ON 25 APR 2006